TuHURA Biosciences (NASDAQ:HURA) Shares Down 2.1% – Here’s What Happened

TuHURA Biosciences, Inc. (NASDAQ:HURA)’s share price was down 2.1% during trading on Monday. The stock traded as low as $1.85 and last traded at $1.87. 334,271 shares were traded during trading, an increase of 63% from the average session volume of 205,660 shares. The stock had previously closed at $1.91.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Friday, July 17th. Citizens Jmp reiterated a “market outperform” rating and issued a $9.00 price objective on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, TuHURA Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Stock Performance

The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.18 and a current ratio of 0.18. The company has a market capitalization of $126.19 million, a PE ratio of -3.67 and a beta of -0.21. The company has a 50 day moving average price of $2.11 and a 200 day moving average price of $2.22.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. Equities analysts forecast that TuHURA Biosciences, Inc. will post -0.55 EPS for the current year.

Institutional Trading of TuHURA Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new position in shares of TuHURA Biosciences in the 2nd quarter worth approximately $81,000. HighTower Advisors LLC raised its position in shares of TuHURA Biosciences by 42.5% during the 2nd quarter. HighTower Advisors LLC now owns 30,151 shares of the company’s stock valued at $71,000 after acquiring an additional 8,999 shares in the last quarter. Two Sigma Securities LLC acquired a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at approximately $33,000. Hsbc Holdings PLC bought a new position in TuHURA Biosciences during the second quarter worth $69,000. Finally, Jefferies Financial Group Inc. bought a new position in TuHURA Biosciences during the second quarter worth $98,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ:HURA) is a clinical-stage biotechnology company focused on developing therapies designed to overcome immune suppression in the tumor microenvironment and improve responses to cancer treatment. The company’s research is centered on immuno-oncology approaches intended to stimulate both innate and adaptive immune responses against tumors.

TuHURA’s lead program, IFx-2, is an investigational intratumoral immunotherapy and cancer vaccine candidate designed to reprogram the tumor environment and promote an immune response.